Ronald De Wit

Professor Ronald De Wit is a Full Professor and Medical Oncologist at the Erasmus MC Cancer Institute, Erasmus University Rotterdam. He specializes in Genitourinary Oncology, focusing on systemic treatments for urothelial, prostate, renal cell, and germ cell cancers. Since 1990, he has led international clinical trials, including pivotal studies in taxane-based chemotherapies and immunotherapies like pembrolizumab. He chairs the Dutch Uro-Oncology Study Group and has held leadership roles in EORTC, ESMO, and ASCO committees. His research integrates translational pathology and urology collaborations, emphasizing biomarker discovery and patient outcomes. He has over 350 publications and received visiting professorships at MSKCC, American University Beirut, and King Hussein Cancer Center.

Education: Medical degree from University of Amsterdam. Career: Erasmus MC since 1990. Research: Key contributions include the CARD trial for cabazitaxel efficacy and the IGCCCG update for germ cell cancer classification. Awards: Multiple visiting professorships and industry advisory roles.

Advising/Grants: Principal investigator in phase III trials, Industry Advisory Board memberships, and Data Monitoring Committees. Labs/Teams: Collaborates with Urology and Translational Pathology departments, leading the Dutch Uro-Oncology Study Group (27 hospitals).